A daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysis
Introduction/Objective Pulmonary embolism (PE) is a relatively common complication of COVID-19. The results of a study published in 2022 show that 10-15% of hospitalized patients suffer from prothrombotic coagulopathy, resulting in arterial or venous thromboembolic events. We are presenting a COVID-...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
City Medical emergency department, Belgrade
2022-01-01
|
| Series: | Halo 194 |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/2334-6477/2022/2334-64772201018S.pdf |
| _version_ | 1818260699818754048 |
|---|---|
| author | Stojanović Duška Stojanović Milovan Marjanović Dušan Mitrović Goran Stalević Marko |
| author_facet | Stojanović Duška Stojanović Milovan Marjanović Dušan Mitrović Goran Stalević Marko |
| author_sort | Stojanović Duška |
| collection | DOAJ |
| description | Introduction/Objective Pulmonary embolism (PE) is a relatively common complication of COVID-19. The results of a study published in 2022 show that 10-15% of hospitalized patients suffer from prothrombotic coagulopathy, resulting in arterial or venous thromboembolic events. We are presenting a COVID-19 patient with PE whose treatment was a challenge because he had developed hemoptysis after being treated with anticoagulant therapy. Case report. We presented a case of a young patient with COVID-19 induced pneumonia, treated with antibiotics, corticosteroids and prophylactic anticoagulant therapy. During his hospitalization, he developed PE which was why the dosage of anticoagulants was increased. Not long after that, the patient developed massive hemoptysis. A team of specialists decided that he was to continue receiving the anticoagulant therapy while simultaneously introducing a hemostatic drug. The patient responded well to the expanded therapy and was discharged from the hospital two weeks later. Conclusion. Based on all pre-COVID medical guidelines, the cornerstone of treating PE is anticoagulant therapy. However, even taking into account significant advances in creating innovative drugs and the absolute clinical necessity of prescribing such therapy, it still comes with a series of complications, the most important of which is significant bleeding. Treating patients with comorbidities, PE and hemoptysis is a complex endeavour, because what helps with one disease may worsen another and vice versa. This is why an individualized treatment approach is necessary for each patient and difficult decisions should be made by a team of specialists. |
| first_indexed | 2024-12-12T18:35:29Z |
| format | Article |
| id | doaj.art-78332b5c5d3f4c8bba86a58358add1cf |
| institution | Directory Open Access Journal |
| issn | 2334-6477 |
| language | English |
| last_indexed | 2024-12-12T18:35:29Z |
| publishDate | 2022-01-01 |
| publisher | City Medical emergency department, Belgrade |
| record_format | Article |
| series | Halo 194 |
| spelling | doaj.art-78332b5c5d3f4c8bba86a58358add1cf2022-12-22T00:15:48ZengCity Medical emergency department, BelgradeHalo 1942334-64772022-01-01281182310.5937/halo28-355412334-64772201018SA daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysisStojanović Duška0Stojanović Milovan1Marjanović Dušan2Mitrović Goran3Stalević Marko4University Clinical Center Niš, Clinic for Infective Diseases, Niš, SerbiaInstitute for Treatment and Rehabilitation Niška Banja, Niš, SerbiaUniversity Clinical Center Niš, Clinic for Infective Diseases, Niš, SerbiaInstitute for Treatment and Rehabilitation Niška Banja, Niš, SerbiaNiš University, Faculty of Medicine, Niš, SerbiaIntroduction/Objective Pulmonary embolism (PE) is a relatively common complication of COVID-19. The results of a study published in 2022 show that 10-15% of hospitalized patients suffer from prothrombotic coagulopathy, resulting in arterial or venous thromboembolic events. We are presenting a COVID-19 patient with PE whose treatment was a challenge because he had developed hemoptysis after being treated with anticoagulant therapy. Case report. We presented a case of a young patient with COVID-19 induced pneumonia, treated with antibiotics, corticosteroids and prophylactic anticoagulant therapy. During his hospitalization, he developed PE which was why the dosage of anticoagulants was increased. Not long after that, the patient developed massive hemoptysis. A team of specialists decided that he was to continue receiving the anticoagulant therapy while simultaneously introducing a hemostatic drug. The patient responded well to the expanded therapy and was discharged from the hospital two weeks later. Conclusion. Based on all pre-COVID medical guidelines, the cornerstone of treating PE is anticoagulant therapy. However, even taking into account significant advances in creating innovative drugs and the absolute clinical necessity of prescribing such therapy, it still comes with a series of complications, the most important of which is significant bleeding. Treating patients with comorbidities, PE and hemoptysis is a complex endeavour, because what helps with one disease may worsen another and vice versa. This is why an individualized treatment approach is necessary for each patient and difficult decisions should be made by a team of specialists.https://scindeks-clanci.ceon.rs/data/pdf/2334-6477/2022/2334-64772201018S.pdfpulmonary embolismcovid-19anticoagulantshemoptysis |
| spellingShingle | Stojanović Duška Stojanović Milovan Marjanović Dušan Mitrović Goran Stalević Marko A daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysis Halo 194 pulmonary embolism covid-19 anticoagulants hemoptysis |
| title | A daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysis |
| title_full | A daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysis |
| title_fullStr | A daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysis |
| title_full_unstemmed | A daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysis |
| title_short | A daily clinical challenge during the COVID-19 pandemic era: How to treat patients with pulmonary embolism and hemoptysis |
| title_sort | daily clinical challenge during the covid 19 pandemic era how to treat patients with pulmonary embolism and hemoptysis |
| topic | pulmonary embolism covid-19 anticoagulants hemoptysis |
| url | https://scindeks-clanci.ceon.rs/data/pdf/2334-6477/2022/2334-64772201018S.pdf |
| work_keys_str_mv | AT stojanovicduska adailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT stojanovicmilovan adailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT marjanovicdusan adailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT mitrovicgoran adailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT stalevicmarko adailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT stojanovicduska dailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT stojanovicmilovan dailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT marjanovicdusan dailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT mitrovicgoran dailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis AT stalevicmarko dailyclinicalchallengeduringthecovid19pandemicerahowtotreatpatientswithpulmonaryembolismandhemoptysis |